G 141
Alternative Names: G-141; SMARCA2 (SM); SMARCA2 modulating therapeutic - Onco3R TherapeuticsLatest Information Update: 25 Dec 2025
At a glance
- Originator Galapagos NV
- Developer Onco3R Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action SMARCA2 protein modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Immunological disorders
Most Recent Events
- 22 Oct 2025 Pharmacodynamics data from a preclinical study in Cancer presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2025 (AACR-NCI-EORTC-2025)
- 22 Oct 2025 Pharmacodynamics data from a preclinical study in Cancer released by Onco3R Therapeutics
- 22 Oct 2025 Onco3R therapeutics announced their plans to initiate IND-enabling studies for cancer in 2026